Biblio
Allogeneic stem cell transplantation for myelofibrosis patients aged ≥ 65 years. Eur J Haematol. 2019.
. Allogeneic Stem Cell Transplantation for patients with lower risk MDS. Biol Blood Marrow Transplant. 2020.
. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016;374(1):43-53.
Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis. Biol Blood Marrow Transplant. 2019.
Enhanced immune reconstitution of γδ T cells after allograft overcomes negative impact of pre-transplant MRD positive status in AML patients.: γδ T cells and MRD+ AML. Transplant Cell Ther. 2021.
. HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transplant. 2018.
Incidence and Outcome of Late Relapse after Allogeneic Stem Cell Transplantation for Myelofibrosis. Biol Blood Marrow Transplant. 2020.
. Outcome after transplantation according to reduced intensity conditioning regimen in patients transplanted for myelofibrosis. Biol Blood Marrow Transplant. 2016.
Reduced intensity hematopoietic stem cell transplantation for myelofibrosis in accelerated-phase. Blood Adv. 2022.
. .